Literature DB >> 15126370

Antitumor activity of a kinesin inhibitor.

Roman Sakowicz1, Jeffrey T Finer, Christophe Beraud, Anne Crompton, Evan Lewis, Alex Fritsch, Yan Lee, John Mak, Robert Moody, Rebecca Turincio, John C Chabala, Paul Gonzales, Stephanie Roth, Steve Weitman, Kenneth W Wood.   

Abstract

Several members of the kinesin family of microtubule motor proteins play essential roles in mitotic spindle function and are potential targets for the discovery of novel antimitotic cancer therapies. KSP, also known as HsEg5, is a kinesin that plays an essential role in formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. We identified a potent inhibitor of KSP, CK0106023, which causes mitotic arrest and growth inhibition in several human tumor cell lines. Here we show that CK0106023 is an allosteric inhibitor of KSP motor domain ATPase with a Ki of 12 nM. Among five kinesins tested, CK0106023 was specific for KSP. In tumor-bearing mice, CK0106023 exhibited antitumor activity comparable to or exceeding that of paclitaxel and caused the formation of monopolar mitotic figures identical to those produced in cultured cells. KSP was most abundant in proliferating human tissues and was absent from cultured postmitotic neurons. These findings are the first to demonstrate the feasibility of targeting mitotic kinesins for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126370     DOI: 10.1158/0008-5472.can-03-3839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.

Authors:  Hanna Jean Khoury; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Maria Cielo Foudray; Martha Arellano; Amelia Langston; Beverly Bethelmie-Bryan; Selena Rush; Kevin Litwiler; Sharon Karan; Heidi Simmons; Adam I Marcus; Mieke Ptaszynski; Hagop Kantarjian
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.

Authors:  Adam I Marcus; Ulf Peters; Shala L Thomas; Sarah Garrett; Amelia Zelnak; Tarun M Kapoor; Paraskevi Giannakakou
Journal:  J Biol Chem       Date:  2005-01-13       Impact factor: 5.157

3.  Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor.

Authors:  Charles Kung; Denise M Kenski; Scott H Dickerson; Russell W Howson; Lee F Kuyper; Hiten D Madhani; Kevan M Shokat
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

4.  Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference.

Authors:  Changjun Zhu; Jian Zhao; Marina Bibikova; Joel D Leverson; Ella Bossy-Wetzel; Jian-Bing Fan; Robert T Abraham; Wei Jiang
Journal:  Mol Biol Cell       Date:  2005-04-20       Impact factor: 4.138

Review 5.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

6.  Dimeric Eg5 maintains processivity through alternating-site catalysis with rate-limiting ATP hydrolysis.

Authors:  Troy C Krzysiak; Susan P Gilbert
Journal:  J Biol Chem       Date:  2006-10-23       Impact factor: 5.157

7.  Anaphase catastrophe is a target for cancer therapy.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Saranya Ravi; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2011-02-02       Impact factor: 12.531

8.  NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site.

Authors:  Sarah S Learman; Catherine D Kim; Nathaniel S Stevens; Sunyoung Kim; Edward J Wojcik; Richard A Walker
Journal:  Biochemistry       Date:  2009-03-03       Impact factor: 3.162

9.  Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

Authors:  Robert Jones; Jacqueline Vuky; Tony Elliott; Graham Mead; José Angel Arranz; John Chester; Simon Chowdhury; Arkadiusz Z Dudek; Volker Müller-Mattheis; Marc-Oliver Grimm; Jürgen E Gschwend; Christian Wülfing; Peter Albers; Jianguo Li; Anna Osmukhina; Jeffrey Skolnik; Gary Hudes
Journal:  Invest New Drugs       Date:  2013-01-18       Impact factor: 3.850

10.  Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.

Authors:  Sentai Ding; Zuohui Zhao; Dingqi Sun; Fei Wu; Dongbin Bi; Jiaju Lu; Naidong Xing; Liang Sun; Haihu Wu; Kejia Ding
Journal:  Tumour Biol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.